ESR1 and neoplasm: Somatic alterations of archival primary tumor tissue and synchronous liver metastases collected at the time of diagnosis, as well as serial plasma samples collected during fourth line treatment with an AKT inhibitor (ipatasertib) were analyzed in a single patient with estrogen receptor (ER) positive, HER2-negative invasive mixed ductal–lobular adenocarcinoma of the breast.